Cancer chemotherapy: A SN-38 (7-Ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug monoTherapy) strategy

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 5, 2003, Pages 947-950

  Angenault, Stéphane ^a   Thirot, Sylvie ^a   Schmidt, Frédéric ^a   Monneret, Claude ^a   Pfeiffer, Bruno ^b   Renard, Pierre ^b  

^a INSTITUT CURIE   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA GLUCURONIDASE; PRODRUG;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY;

EID: 0037430448     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01080-6     Document Type: Article

References (25)

1. Wall M., Wani M., Cook C., Palmar K., McPhail A., Sim G. J. Am. Chem. Soc. 88:1966;3888.
2. Hsiang Y.-H., Liu L. Cancer Res. 48:1988;1722.
3. Pourquier P., Pommier Y. Bull. Cancer (special issue) December. 1998;5.
4. Wall M., Wani M., Nicholas A., Manikumar G., Tele C., Moore L., Truesdale A., Leitner P., Besterman J. J. Med. Chem. 36:1993;2689.
5. Takimoto C., Wright J., Arbuck S. Biochim. Biophys. Acta. 1400:1998;107.
6. Sawada S., Okajima S., Aiyama R., Nokata K., Furuta T., Yokokura T., Sugino E., Yamaguchi K., Miyasaka T. Chem. Pharm. Bull. 39:1991;1446.
7. Sawada S., Matsuoka S., Nokata K., Nagata H., Furuta T., Yokokura T., Miyasaka T. Chem. Pharm. Bull. 39:1991;3183.
8. Narita M., Nagai E., Hagiwara H., Aburada M., Yokoi T., Kamataki T. Xenobiotica. 23:1993;5 Narita M., Nagai E., Hagiwara H., Aburada M., Yokoi T., Kamataki T. Drugs Future. 23:1998;331.
9. Narita M., Nagai E., Hagiwara H., Aburada M., Yokoi T., Kamataki T. Xenobiotica. 23:1993;5 Narita M., Nagai E., Hagiwara H., Aburada M., Yokoi T., Kamataki T. Drugs Future. 23:1998;331.
10. Fujita Y., Yaegashi T., Sawada S., Oyama H., Yoshimoto T., Tsuru D. Biol. Pharm. Bull. 18:1995;648.
11. Bosslet K., Czech J., Hoffmann D. Tumor Targeting. 1:1995;45.
12. Mürdter T., Sperker B., Kivistö K., McClellan M., Fritz P., Friedel G., Linder A., Bosslet K., Toomes H., Diekesmann R., Kroemer H. Cancer Res. 57:1997;2440.
13. Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H.K., Gesson J.-P., Koch M., Monneret C. Cancer Res. 58:1998;1195.
14. Leu Y.-L., Roffler S., Chern J.-W. J. Med. Chem. 42:1999;3623.
15. Prijovich Z., Chen B., Leu Y.-L., Chern J.-W., Roffler R. Br. J. Cancer. 86:2002;1634.
16. Carl P., Chakravarty P., Katzenellenbogen J. J. Med. Chem. 24:1981;479.
17. Andrianomenjanahary S., Dong X., Florent J.-C., Gaudel G., Gesson J.-P., Jacquesy J.-C., Koch M., Michel S., Mondon M., Monneret C., Petit P., Renoux B., Tillequin F. Bioorg. Med. Chem. Lett. 2:1992;1093.
18. Schmidt F., Monneret C. J. Chem. Soc., Perkin Trans. 1. 2002;1302.
19. Desbene S., van Dufat-Trinh H., Michel S., Tillequin F., Koch M., Schmidt F., Florent J.-C., Monneret C., Straub R., Czech J., Gerken M., Bosslet K. Anti-Cancer Drug Des. 14:1999;93.
20. Schmidt F., Ungureanu I., Duval R., Pompon A., Monneret C. Eur. J. Org. Chem. 2001;2129.
21. Schmidt F., Florent J.-C., Monneret C., Straub R., Czech J., Gerken M., Bosslet K. Bioorg. Med. Chem. Lett. 7:1997;1071.
22. Alley M., Scudiero D., Monks A., Hursey M., Czerwinski M., Fine D., Abbott B., Mayo J., Shoemaker R., Boyd M. Cancer Res. 48:1988;589.
23. For the stability measurements, a solution of 250 μg/mL of prodrug in 0.02 M phosphate buffer (pH 7.2) was incubated at 37°C. Aliquots (40 μL) were taken at various times and analyzed by HPLC after dilution with eluent (120 μL). HPLC conditions: analysis was carried out on a reverse-phase column (Spherisorb C18) using isocratic conditions (1 mL/min) of 60% phosphate buffer (0.02 M, pH 3) and 40% acetonitrile with UV detection at 265 nm.
24. Akimoto K., Kawai A., Ohya K. Chem. Pharm. Bull. 42:1994;2135.
25. For the kinetic measurements, a solution of 300 μM of prodrug in 0.02 M phosphate buffer (pH 7.2) was incubated at 37°C in the presence of 10 units/mL of β-D-glucuronidase (E. coli). Aliquots (40 μL) were taken at various times and analyzed by HPLC after dilution with eluent (120 μL). HPLC conditions: analysis was carried out on a reverse-phase column (WATERS X-terra, 250/4.6 mm) using isocratic conditions (1 mL/min) of 70% triethylammonium acetate buffer (0.1%, pH 9) and 30% acetonitrile with UV detection at 265 nm (extracted from PDA 3-D spectra).